Birk NK, Jain S, Massoud L, Ramesh D, Monday L, Muma B, Williams J, Alangaden G, and Ramesh M. Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients. Open Forum Infect Dis 2022; 9(7):ofac282.
Open Forum Infect Dis
We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients.